News Releases



Olaparib Tablet Safe in Pretreated Ovarian Cancer Patients; More Effective in Those With BRCA Mutations2947529/10/2014 1:56:39 AM97 Releases/AllItems.aspx590False2014-09-09T23:05:00Z<div class="ExternalClass982442D89BF045EEAD5C38B49DD23A7C"><p>​SEATTLE — An oral tablet form of a PARP inhibitor, olaparib, given in combination with chemotherapy, was safe in heavily pretreated ovarian cancer patients, and patients with BRCA mutations may have a better response compared with those without a BRCA mutation, according to phase Ib clinical trial data presented at the <a href="http&#58;//" target="_blank">Marsha Rivkin Center for Ovarian Cancer Research-AACR 10th Biennial Ovarian Cancer Research Symposium</a>, held Sept. 8-9.&#160;</p><p><img src="/PublishingImages/Rivkin_Saul_150x200.jpg" alt="" style="margin&#58;5px 20px;vertical-align&#58;auto;float&#58;right;" />&quot;This study is one of the first studies to use olaparib tablets instead of olaparib capsules,&quot; said <a href="http&#58;//" target="_blank">Saul Rivkin, MD</a>, founder and chairman of the <a href="http&#58;//" target="_blank">Marsha Rivkin Center for Ovarian Cancer Research</a>, and a research scientist at the <a href="http&#58;//" target="_blank">Swedish Cancer Institute</a>, both in Seattle, Washington. &quot;The goal was to find the maximum tolerated dose of olaparib tablets plus weekly metronomic carboplatin and paclitaxel in patients with relapsed ovarian cancer.</p><p>&quot;This treatment regimen provided a response rate of 66 percent in heavily pretreated ovarian cancer patients. It was surprisingly tolerable with no grade 4 toxicities,&quot; said Rivkin.</p><p>&quot;The outlook for ovarian cancer patients with advanced disease is not equivalent to that of breast cancer, and a lot of work needs to be done to improve the cure rate,&quot; Rivkin added. &quot;Medical researchers are discovering and investigating new and innovative therapies for the treatment of ovarian cancer. We are constantly working toward improving the quality of life and survival for all ovarian cancer patients.&quot;</p><p>Rivkin and colleagues enrolled 14 heavily pretreated ovarian cancer patients (from three to eight prior therapies), ages 42 to 77. Patients received paclitaxel and carboplatin weekly, three weeks out of four, with increasing doses of olaparib. The maximum tolerated dose of olaparib was found to be 150 mg twice daily for three consecutive days of each week of each cycle.</p><p>Of the 12 evaluable patients, four had a complete response (33 percent), four had a partial response (33 percent), two had stable disease (16 percent), and two had disease progression (16 percent).&#160;</p><p>Three patients with a complete response, three with a partial response, one with stable disease, and one with disease progression had BRCA mutations detected in their tumors.</p><p>The most common grade 3 toxicities included neutropenia, leukopenia, lymphopenia, and anemia. There was no evidence of gastrointestinal, renal, cardiac, hepatic, pulmonary, or dermatologic toxicities in any of the patients with a toxicity grade greater than 2.</p><p>The investigators plan to recruit up to 40 additional patients in the phase II extension of this protocol.</p><p>This study was funded by the Dulien Fund and AstraZeneca. Rivkin declares no conflicts of interest.</p></div>
AACR Issues Policy Statement to Urge FDA to Provide Oversight of High Risk Laboratory Developed Tests to Protect Patient Safety and Product Innovation2913519/9/2014 12:31:17 PM85 Releases/AllItems.aspx589False2014-09-09T04:05:00ZAACR immediate past president to testify on Capitol Hill on the issue<div class="ExternalClassD12E6157C83F4890BA7821DDAE287A84"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR) issued a <a href="http&#58;//" target="_blank">policy statement</a> Tuesday, Sept. 9, that underscores the importance of safe, accurate, and effective diagnostic tests by recommending that the U.S. Food and Drug Administration (FDA) begin to actively exert its authority to regulate high-risk laboratory developed tests (LDTs) that are being utilized by physicians to make treatment decisions, including the tailoring of an individual's cancer treatment regimen.</p><p><img src="/PublishingImages/Sawyers_Charles_150x200.jpg" alt="" style="margin&#58;5px 20px;vertical-align&#58;auto;float&#58;right;" />&quot;FDA's policy of enforcement discretion over LDTs was acceptable when these tests were mostly routine laboratory procedures; however, as LDTs have evolved in complexity, the risk posed to patients has also increased,&quot; said Charles L. Sawyers, MD, immediate past president of the AACR, chair of the Human Oncology and Pathogenesis Program at the Memorial Sloan Kettering Cancer Center in New York, and co-author of the policy statement. &quot;It is therefore vital that all diagnostic tests used to make high-risk treatment decisions be FDA-approved, so patients and physicians can be assured of the test's safety and accuracy,&quot; he said.</p><p>&quot;Diagnostic tests play a central role in the success of personalized medicine by helping oncologists identify the right treatment for the right patient,&quot; said Margaret Foti, PhD, MD (hc) chief executive officer of the AACR. &quot;Therefore, we strongly support the FDA exerting its authority to regulate LDTs that pose a high risk to cancer patients.&quot;</p><p>The AACR believes that a robust, predictable, and reliable evidence-based regulatory framework will ensure that future treatments and cures will reach patients in an efficient and expeditious manner. Implementation of a risk-based framework by the FDA that would provide for evaluation of all high-risk molecular diagnostic tests would balance the need for encouraging innovative medical product development with the need for ensuring patient safety.</p><p>&quot;Having a single approval standard for all tests regardless of origin would also create a more predictable regulatory and investment climate for both the diagnostics and the pharmaceutical industries,&quot; said Laura van 't Veer, PhD, director of applied genomics at UCSF Helen Diller Family Comprehensive Cancer Center and co-author of the policy statement.</p><p>&quot;As an oncologist, I rely on these complex diagnostic test results to make treatment decisions,&quot; said Carlos L. Arteaga, MD, AACR president and professor of medicine and cancer biology, and associate director for clinical research at the Vanderbilt-Ingram Cancer Center of Vanderbilt University, Nashville, Tennessee. &quot;I need to be confident in the test results that form the basis of high-risk treatment decisions for my patients, whether these tests are developed as LDTs or as kits approved by the FDA.&quot;</p></div>
Research Finds No Association Between Wearing a Bra and Breast Cancer2813409/5/2014 1:17:21 PM125 Releases/AllItems.aspx588False2014-09-05T04:05:00Z<div class="ExternalClass176857BAE2A94088804AE8F8467D235F"><p>PHILADELPHIA — A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in <em><a href="http&#58;//" target="_blank">Cancer Epidemiology, Biomarkers &amp; Prevention</a></em>, a journal of the American Association for Cancer Research. <img src="/PublishingImages/Chen_Lu_150x200.jpg" alt="" style="margin&#58;10px;float&#58;right;vertical-align&#58;auto;" /></p><p>“There have been some concerns that one of the reasons why breast cancer may be more common in developed countries compared with developing countries is differences in bra-wearing patterns,” said Lu Chen, MPH, a researcher in the <a href="http&#58;//" target="_blank">Public Health Sciences Division</a> at Fred Hutchinson Cancer Research Center and a doctoral student in the Department of Epidemiology at the University of Washington School of Public Health. “Given how common bra wearing is, we thought this was an important question to address.</p><p>“Our study found no evidence that wearing a bra increases a woman’s risk for breast cancer. The risk was similar no matter how many hours per day women wore a bra, whether they wore a bra with an underwire, or at what age they first began wearing a bra,” said Chen.</p><p>“There has been some suggestion in the lay media that bra wearing may be a risk factor for breast cancer. Some have hypothesized that drainage of waste products in and around the breast may be hampered by bra wearing. Given very limited biological evidence supporting such a link between bra wearing and breast cancer risk, our results were not surprising,” Chen added. </p><p>According to the study authors, this study characterizes various bra-wearing habits in relation to breast cancer risk using a rigorous epidemiological study design. “The findings provide reassurance to women that wearing a bra does not appear to increase the risk for the most common histological types of postmenopausal breast cancer,” the authors noted.</p><p>Study participants were 454 women with invasive ductal carcinoma (IDC) and 590 women with invasive lobular carcinoma (ILC), the two most common subtypes of breast cancer, from the Seattle-Puget Sound metropolitan area; 469 women who did not have breast cancer served as controls. All women were postmenopausal, ages 55 to 74.</p><p>The researchers conducted in-person interviews and obtained information on demographics, family history, and reproductive history. They also asked a series of structured questions to assess lifetime patterns of bra wearing. Questions included age at which the study participant started wearing a bra, whether she wore a bra with an underwire, her bra cup size and band size, the number of hours per day and number of days per week she wore a bra, and if her bra-wearing patterns ever changed at different times in her life.</p><p>No aspect of wearing a bra was associated with an increased risk for either IDC or ILC.</p><p>This study was funded by the National Cancer Institute. Chen declares no conflicts of interest.​</p></div>
Pancreatic Cancer Action Network and American Association for Cancer Research Invite Applications for 2015 Research Grants2719549/2/2014 3:44:47 PM54 Releases/AllItems.aspx587False2014-09-02T13:00:00Z<div class="ExternalClassCDC363A2DAD54124B6620FEFB935EB9C"><p>PHILADELPHIA — The American Association for Cancer Research (AACR) and the <a href="http&#58;//" target="_blank">Pancreatic Cancer Action Network</a> are pleased to announce the opening of the 2015 research grants program, which offers $2.2 million to support research that has direct application and relevance to pancreatic cancer.</p><p>Three grant mechanisms are being offered that collectively target postdoctoral and clinical fellows, and junior and senior independent researchers. These grant mechanisms are the highly coveted Research Acceleration Network (RAN) Grant, which provides $1 million in funding to support team science and accelerate medical breakthroughs in pancreatic cancer, the Career Development Awards, and the Pathway to Leadership Grant. </p><p>“Pancreatic cancer is a devastating disease with a poor prognosis; it has a five-year survival rate of only 6 percent,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “The AACR is proud to continue its partnership with the Pancreatic Cancer Action Network on grant opportunities designed to advance our understanding of pancreatic cancer, because more research is urgently needed if we are to accelerate the pace of progress against this deadly disease and improve patient outcomes.”</p><p>Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2030, according to <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=541">research</a> conducted by the Pancreatic Cancer Action Network and recently published in <em>Cancer Research</em>, a journal of the AACR.</p><p>“We are working to build a robust pancreatic cancer research community through our grants program and we are thrilled to partner with organizations like the AACR,” said Julie Fleshman, president and chief executive officer of the Pancreatic Cancer Action Network. “Over the years, our grant recipients have made significant progress towards the understanding of pancreatic cancer, improved diagnostic tools, and novel treatment modalities.” </p><p>Since the Pancreatic Cancer Action Network–AACR grants program was introduced in 2003, more than $21.5 million have been awarded to accelerate pancreatic cancer research.<br>Submissions for 2015 grants must be completed online using the <a href="https&#58;//" target="_blank">proposalCENTRAL website</a>. Funding decisions will be announced in March and the grant term will begin July 1, 2015. The recipients will be honored at the <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=25">AACR Annual Meeting 2015</a>, held in Philadelphia, April 18-22. Please see below for grant deadlines.</p><p>Applications are being accepted for the following grant mechanisms&#58; </p><p><strong>Research Acceleration Network Grant </strong></p><p>This grant mechanism, now in its third year, provides $1 million over one to three years to support a project currently underway within the pancreatic cancer research community that is ready to be accelerated, that includes a clinical component, and that will help double survival for pancreatic cancer by the year 2020. The grant is open to independent investigators and needs to be implemented by at least two co-principal investigators from distinct institutions.</p><p>The deadline for the Letter of Intent is noon ET, Oct. 8, 2014.&#160; <br></p><p><strong>Career Development Awards</strong></p><p>Career Development Awards are two-year grants totaling $200,000 to support newly independent investigators develop or strengthen their research program in pancreatic cancer.<br>The application deadline is noon ET, Oct. 29, 2014.&#160; <br></p><p><strong>Pathway to Leadership Grant </strong></p><p>The Pathway to Leadership Grant is a five-year grant totaling $600,000 that is designed to build future leadership in the pancreatic cancer research community by supporting a highly promising postdoctoral or clinical research fellow during his or her mentored research and continuing through the early phase of independence. </p><p>The application deadline is noon ET, Oct. 29, 2014.&#160; </p><p>To learn more about the 2015 grants program, visit <a href="/funding"></a> or <a href="http&#58;//" target="_blank"></a>.</p><p><a href="http&#58;//" target="_blank">Meet</a> the past grant recipients and learn more about their funded projects.&#160; ​</p></div>
AACR to Co-host 2014 Turning the Tide Against Cancer National Conference2541778/26/2014 6:52:54 PM77 Releases/AllItems.aspx586False2014-08-26T04:00:00Z<div class="ExternalClass8461C5384D424BFBBA25BC9BAC3C97D3"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR), the Personalized Medicine Coalition, and Feinstein Kean Healthcare are convening the second national conference on <a href="http&#58;//" target="_blank">Turning the Tide Against Cancer Through Sustained Medical Innovation</a> which will be held 8&#58;30 a.m. to 4 p.m., Oct. 9, at the Knight Conference Center at the Newseum in Washington, D.C. <br><br>The conference will continue the dialogue on patient-centered cancer research and care and will discuss potential policy solutions that align with scientific advances and support innovation while addressing the issue of rising health care costs. It will engage the broader stakeholder community to help identify specific policy pathways aimed at supporting the shift to patient-centered cancer research and care and addressing the value and cost of cancer care.<br><br><a href="https&#58;//;oseq=&amp;c=&amp;ch=&amp;zbrandid=4017&amp;zidType=CH&amp;zid=24287158&amp;zsubscriberId=1056828440&amp;zbdom=http&#58;//" target="_blank">Register</a> for the conference, which is free to members of the press.<br><br><a href="http&#58;//;siteid=aacrjnls&amp;ijkey=6zXz3V7qFG.d6%29." target="_blank">Read</a> the 2014 Turning the Tide Against Cancer paper published in Clinical Cancer Research, a journal of the AACR.<br><br><a href="http&#58;//" target="_blank">Learn more</a> about Turning the Tide Against Cancer initiative.<br><br><a href="http&#58;//;zidType=CH&amp;zid=24287161&amp;zsubscriberId=1056828440&amp;zbdom=http&#58;//" target="_blank">View the agenda</a> for featured panels, sessions, and speakers.</p></div>
Cigarettes With Reduced Nicotine May Not Increase Smoking Intensity2436088/22/2014 1:47:08 PM90 Releases/AllItems.aspx585False2014-08-22T04:05:00Z<div class="ExternalClass3669D791C0314ECE9D7CCE4A3B9DC41C"><p>​PHILADELPHIA — Adults who smoked reduced-nicotine cigarettes did not smoke with more intensity to compensate for the lower levels of nicotine, and therefore were not exposed to more toxic chemicals, according to a study published in <a href="http&#58;//" target="_blank">Cancer Epidemiology, Biomarkers &amp; Prevention</a>, a journal of the American Association for Cancer Research.</p><p><img src="/PublishingImages/Hammond_David_150x200.jpg" alt="" style="margin&#58;5px 20px;vertical-align&#58;auto;float&#58;right;" />&quot;As a result of the 2009 Tobacco Act, the U.S. Food and Drug Administration [FDA] has the mandate to reduce nicotine levels in cigarettes to negligible amounts,&quot; said <a href="https&#58;//" target="_blank">David Hammond, PhD</a>, associate professor in the School of Public Health and Health Systems of the <a href="https&#58;//" target="_blank">University of Waterloo</a> in Ontario, Canada.</p><p>&quot;One of the primary barriers to doing so has been a concern that individuals who continue to smoke will be exposed to greater amounts of toxic chemicals in smoke as they try to extract more nicotine from cigarettes,&quot; explained Hammond. &quot;The current study suggests that this may not be the case.</p><p>&quot;Our study suggests that smokers are unable or unwilling to compensate when there is markedly less nicotine in the cigarette and when the experience of smoking is far less rewarding. Our study may help regulators anticipate the possible consequences of mandatory nicotine reductions in cigarettes,&quot; said Hammond.</p><p>Hammond and colleagues recruited to the study 72 adult smokers, ages 18 to 65, 42 female and 30 male. After completing a smoking history and demographic data survey, participants smoked their usual brand of cigarettes for one week. During the next three weeks, they smoked Quest 1, Quest 2, and Quest 3 cigarettes, in that sequence, one brand a week. Participants provided urine and breath samples at the end of each week.</p><p>Quest 1, Quest 2, and Quest 3 cigarettes have nicotine emission levels of 0.6 mg, 0.3 mg, and 0.05 mg or less, respectively, as opposed to about 1.2 mg in regular cigarettes.</p><p>At the end of the study, the researchers found no difference in the number of cigarettes used by the participants, irrespective of the brand; no difference in the number of puffs they took from different brands; no difference in the amount of post-cigarette carbon monoxide levels in their breath; and no difference in urine levels of 1-hydroxypyrene, a chemical in cigarettes with cancer-causing potential.</p><p>Cotinine, a breakdown product of nicotine often measured to estimate nicotine levels, however, fell by 34 percent and 55 percent in the participants' urine, after smoking Quest 2 and Quest 3 cigarettes, respectively.</p><p>About 44 percent of the study participants reported smoking non-Quest cigarettes during the Quest 3 study period.</p><p>This study was funded by the Health Canada Tobacco Control Program, a Canadian Institutes of Health Research New Investigator Award, and a Canadian Cancer Society Research Institute Junior Investigator Award. Hammond declares no conflicts of interest.</p></div>
AACR Invites Nominations for 2015 Team Science and Immunology Awards2312338/18/2014 1:40:46 PM70 Releases/AllItems.aspx583False2014-08-15T04:00:00Z<div class="ExternalClass67263F9D0E4B415693820B0AA62C5141"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR) announces a call for nominations for the Ninth Annual AACR Team Science Award and the Third Annual AACR-<a target="_blank" href="http&#58;//">Cancer Research Institute</a> (CRI) Lloyd J. Old Award in Cancer Immunology.<br><br>The awards will be presented during the <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=25">AACR Annual Meeting 2015</a>, which will be held April 18-22, in Philadelphia.<br><br><strong><a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=8">Ninth Annual AACR Team Science Award</a></strong><br><br>The AACR Team Science Award was established to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. The award will recognize an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or likely will advance our fundamental knowledge of cancer or a team that has applied existing knowledge to advance the detection, diagnosis, prevention or treatment of cancer.<br><br>The team selected to receive the AACR Team Science Award will collectively be awarded an honorarium of $50,000.<br><br>Last year’s award was presented to the <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=472">Duke University/Johns Hopkins University/National Cancer Institute Malignant Brain Tumor Team</a>, led by Darell Doty Bigner, MD, PhD, director of the Preston Robert Tisch Brain Tumor Center and the Pediatric Brain Tumor Foundation Institute at Duke University School of Medicine.<br><br>The Ninth Annual AACR Team Science Award is generously supported by Eli Lilly and Company.<br><br><strong><a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=2">Third Annual AACR-CRI Lloyd J. Old Award in Cancer Immunology</a></strong><br><br>The AACR-CRI Lloyd J. Old Award in Cancer Immunology was established to honor the memory of the late Lloyd J. Old and will recognize an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field. <br><br>Last year’s honoree was <a href="/Pages/News-Release-Detail.aspx?ItemID=470">Robert D. Schreiber, PhD</a>, alumni endowed professor of pathology an immunology, professor of molecular microbiology, and director of the Center for Human Immunology and Immunotherapy Programs at Washington University School of Medicine in St. Louis. His award lecture was titled, “Cancer Immunoediting&#58; Applying Mechanistic Insights to Cancer Immunotherapy.”<br><br>In addition to presenting a 50-minute lecture at the AACR Annual Meeting 2015, the recipient will receive an honorarium of $10,000.<br><br></p><ul><li>Nominations for these awards must be submitted by 4 p.m. ET, Wednesday, Sept. 3, 2014.</li></ul><p></p><ul><li>For more information, contact Monique P. Eversley at <a href="mailto&#58;"></a> or visit <a href="/Research/Awards/Pages/Awards-Listing.aspx">http&#58;// </a></li></ul><p></p></div>
Nominations Open for 2015 Pezcoller-AACR International Award2313888/18/2014 2:25:19 PM60 Releases/AllItems.aspx584False2014-08-15T04:00:00Z<div class="ExternalClass4DF8605E647C446388358728B43C61E8"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR) announces a call for nominations for the 18th annual Pezcoller Foundation-AACR International Award for Cancer Research.<br><br>The awards will be presented during the <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=25">AACR Annual Meeting 2015</a>, which will be held April 18-22, in Philadelphia.<br><br>The <a href="/Research/Awards/Pages/Awards-Detail.aspx?ItemId=16">Pezcoller Foundation-AACR International Award</a> was established in 1997 to recognize a scientist of international renown who has made a major scientific discovery in basic cancer research or who has made significant contributions to translational cancer research, who continues to be active in cancer research and has a record of recent, noteworthy publications, and whose ongoing work holds promise for continued substantive contributions to progress in the field of cancer.<br><br>Last year’s award was presented to <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=476">Elaine Fuchs, PhD</a>, Rebecca C. Lancefield professor and head of the Laboratory of Mammalian Cell Biology and Development at The Rockefeller University in New York. Her lecture was titled, “Stem Cells in Science, Action, and Cancer.”<br><br>In addition to the 50-minute award lecture presented at the AACR Annual Meeting 2015, the recipient will receive an honorarium of 75,000 euros. The recipient will also present the 10th annual Stanley J. Korsmeyer Lecture at the Venetian Institute for Molecular Medicine in Padua, Italy, prior to the Pezcoller Foundation’s official award ceremony in Trento, Italy, May 2015.<br><br></p><ul><li>Nominations for this award must be submitted by 4 p.m. ET, Wednesday, Sept. 10, 2014.</li></ul><p></p><ul><li>For more information, contact Monique P. Eversley at <a href="mailto&#58;" target="_blank"></a> or visit <a href="/Research/Awards/Pages/Awards-Listing.aspx">http&#58;//</a>.</li></ul><p></p></div>
NSAIDs May Lower Breast Cancer Recurrence Rate in Overweight and Obese Women2205398/14/2014 1:17:43 PM111 Releases/AllItems.aspx582False2014-08-14T04:05:00Z<div class="ExternalClass7EA47BFD999049BCBA003C2480B52607"><p>PHILADELPHIA — Recurrence of hormone-related breast cancer was cut by half in overweight and obese women who regularly used aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), according to data published in <em><a href="http&#58;//" target="_blank">Cancer Research</a></em>, a journal of the American Association for Cancer Research. <img alt="Linda A. deGraffenried, PhD" src="/PublishingImages/deGraffenried_Linda_150x200.jpg" style="margin&#58;10px;float&#58;right;vertical-align&#58;auto;" /></p><p>“Our studies suggest that limiting inflammatory signaling may be an effective, less toxic approach to altering the cancer-promoting effects of obesity and improving patient response to hormone therapy,” said <a href="http&#58;//" target="_blank">Linda A. deGraffenried, PhD</a>, associate professor of nutritional sciences at The University of Texas in Austin.</p><p>The study found that women whose body mass index (BMI) was greater than 30 and had estrogen receptor alpha (ERα)-positive breast cancer had a 52 percent lower rate of recurrence and a 28-month delay in time to recurrence if they were taking aspirin or other NSAIDs.</p><p>“These results suggest that NSAIDs may improve response to hormone therapy, thereby allowing more women to remain on hormone therapy rather than needing to change to chemotherapy and deal with the associated side effects and complications,” said deGraffenried. “However, these results are preliminary and patients should never undertake any treatment without consulting with their physician.”</p><p>Using blood from obese patients, deGraffenried and colleagues conducted experiments in the laboratory to recreate a tumor environment containing cancer cells, fat cells, and the immune cells that promote inflammation. They found that the factors associated with obesity initiate a network of signaling within the tumor environment to promote growth and resistance to therapy.</p><p>“These studies show that the greatest benefit from aspirin [and other NSAIDs] will be in those with a disease driven by inflammation, and not just obesity,” explained DeGraffenried.</p><p>Researchers used data from 440 women diagnosed with invasive, ERα-positive breast cancer and treated at The University of Texas Health Science Center and the START Center for Cancer Care clinic, both in San Antonio, Texas, between 1987 and 2011.</p><p>Of the women studied, 58.5 percent were obese and 25.8 percent were overweight. About 81 percent took aspirin, and the rest took another NSAID. About 42 percent and 25 percent took statins and omega-3 fatty acid, respectively.</p><p>There was an indication of protection from aspirin and other NSAIDs even after controlling for statins and omega-3 fatty acid use, which also have anti-inflammatory effects.</p><p>This study was funded by the U.S. Department of Defense, the Breast Cancer Research Program of the Congressionally Directed Medical Research Programs, and the National Cancer Institute. DeGraffenried declares no conflicts of interest.​</p></div>
Leading Cancer Organizations Urge FDA to Regulate All Tobacco Products2122548/11/2014 8:34:40 PM130 Releases/AllItems.aspx581False2014-08-11T20:30:00ZAACR, ASCO Issue Joint Response to Proposed Rule<div class="ExternalClassA08FD0B6C4844AE0B236013BCC9935F3"><p>PHILADELPHIA — The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), in a joint letter responding to a proposal by the U.S. Food and Drug Administration (FDA) to extend its regulatory authority over tobacco products, today urged the agency to regulate electronic cigarettes (e-cigarettes), cigars, and all other tobacco products and to strengthen the proposed regulations for newly deemed products. </p><p>“There is no safe form of tobacco use,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “Tobacco is the leading cause of preventable deaths in the United States, and among its dire health consequences are 18 different types of cancer. It is imperative that the FDA takes action to regulate all tobacco products. The future health of the American people, in particular our nation’s children, depends on it.”</p><p>The AACR and ASCO applauded the FDA’s proposal to regulate e-cigarettes. “We believe it is vitally important for the FDA to begin regulating these products, especially because we don’t know much about the health effects of e-cigarette use. We are also quite concerned that e-cigarettes may increase the likelihood that nonsmokers or former smokers will use combustible tobacco products or that they will discourage smokers from quitting,” said Peter P. Yu, MD, FASCO, president of ASCO. </p><p>“There are insufficient data on the long-term health consequences of e-cigarettes, their value as tobacco cessation aids, or their effects on the use of conventional cigarettes. Any benefits of e-cigarettes are most likely to be realized in a regulated environment in which appropriate safeguards can be implemented,” said Roy S. Herbst, MD, PhD, chair of the AACR Tobacco and Cancer Subcommittee and chief of medical oncology at Yale Comprehensive Cancer Center. </p><p>The AACR and ASCO support many of the FDA’s proposals for regulating e-cigarettes and other products, but urge the agency to do more. Specifically, preventing children from using tobacco products is crucial and can be achieved by efforts such as banning youth-oriented advertising and marketing, self-service product displays, and tobacco company sponsorship of youth-oriented events, in addition to restricting sales to minors and implementing age-verification procedures for internet sales.</p><p>Expressing grave concern about the proliferation of flavored e-cigarettes, the AACR and ASCO encouraged the agency to ban e-cigarette flavors or flavor names that are brand names of candy, cookies, soda, and other such products, and to prohibit e-cigarettes containing candy and other youth-friendly flavors, unless there is evidence demonstrating that they do not encourage young people to use these products.</p><p>The AACR and ASCO strongly discouraged the FDA from exempting “premium” cigars from regulation, an option the agency is considering. “All cigars pose serious health risks,” said Graham Warren, MD, PhD, chair of ASCO’s Tobacco Cessation and Control Subcommittee. “As the FDA itself noted in the proposed rule, even cigar smokers who do not inhale have a seven to 10 times higher overall risk of mouth and throat cancer compared with individuals who have never smoked. Exempting these dangerous products from FDA regulation is clearly not in the best interest of public health.”</p><p>Noting that both large and small cigars are of increasing interest to youth and adult users, the AACR and ASCO underscored that the continued availability of premium cigars in an unregulated market, compounded with the ability of the tobacco industry to strategically market its products to youths and young adults, could reverse the progress made in reducing youth tobacco use.</p><p>Finally, the AACR and ASCO urged the FDA to drop the “consumer surplus” discount used to assess the net impact of the proposed deeming rule. This discount allows the FDA to only consider 30 percent of the benefits achieved via tobacco cessation due to the costs associated with this proposed regulation, including the “lost pleasure” of smoking. The AACR and ASCO stressed that addiction is an unwelcome burden for many tobacco users and that many consumers are not making rational and fully informed choices when initiating and continuing their use of tobacco products.</p><p><a href="/AdvocacyPolicy/GovernmentAffairs/Documents/AACR%20ASCO%20Comments%20on%20FDA%20Proposed%20Tobacco%20Deeming%20Rule-FINAL.pdf" target="_blank">Read</a> the joint AACR and ASCO letter to the FDA ​(<a href="http&#58;//" target="_blank">Adobe Reader</a> required).</p></div>